Survey of cancer genetics: Genetic testing implications

Cancer

Volumn 80, Issue 3 SUPPL., 1997, Pages 523-532

  Lynch, Henry T ^a   Fusaro, Ramon M ^a   Lemon, Stephen J ^a   Smyrk, Thomas ^a   Lynch, Jane ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic counseling; Genetic testing; Hereditary cancer syndromes; Molecular genetics

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; CONFERENCE PAPER; FAMILIAL CANCER; GENETIC SCREENING; HUMAN; MELANOMA; NEUROFIBROMATOSIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; VON HIPPEL LINDAU DISEASE;

EID: 0030755547     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19970801)80:3+<523::aid-cncr1>3.0.co;2-a     Document Type: Conference Paper

References (67)

1. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome): an updated review. Cancer 1996;78:1149-67.
2. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin J. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996;110:682-7.
3. Lynch HT, Smyrk T. Colorectal cancer, survival advantage, and hereditary nonpolyposis colorectal cancer. Gastroenterology 1996;110:943-7.
4. Lynch HT, Mulcahy GM, Harris RE, Guirgis HA, Lynch JF. Genetic and pathologic findings in a kindred with hereditary sarcoma breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer 1978;41:2055-64.
5. Lynch HT, Radford B, Lynch JF. SBLA syndrome revisited. Oncology 1990;47:75-9.
6. Malkin D, Li FP, Stron LC, Fraumeni JF Jr., Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990;250:1233-8.
7. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-21.
8. Sidransky D. Is human patched the gatekeeper of common skin cancers? Nat Genet 1996;14:7-8.
9. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al. The role of the human homologue Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996;14:78-81.
10. Grosfeld FJM, Lips CJM, Beemer FA. Psychosocial consequences of DNA analysis for MEN type 2. Oncology 1996;10:141-6.
11. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996;31:177-81.
12. Cawthon RM, Weiss R, Xu G, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure and point mutations. Cell 1990;62:193-201.
13. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181-6.
14. Cummings LM, Trent JM, Marchuk DA. Identification and mapping of type 1 neurofibromatosis (NF1) homologous loci. Cytogenet Cell Genet 1996;73:334-40.
15. Shannon KM, O'Connell GA, Martin GA, Paderanga K, Olson K, Dinndorf P, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994;330:597-601.
16. Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis. Baltimore: Johns Hopkins University Press, 1992.
17. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-39.
18. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-75.
19. Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni JF Jr. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidermiol 1988;128:324-36.
20. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991;10:183-96.
21. Caldas C, Hahn SA, da Costa-Luis T, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
22. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995;10:351-3.
23. INK4 mutations. N Engl J Med 1995;333:970-4.
24. Whelan AJ, Bartsch D, Goodfellow PJ. A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-7.
25. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
26. Lynch HT. Genetics and pancreatic cancer. Arch Surg 1994;129:266-8.
27. Lynch HT, Fusaro L, Lynch JF. Familial pancreatic cancer: a family study. Pancreas 1992;7:511-5.
28. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985;52:271-3.
29. Lynch HT, Fusaro RM, Kimberling WJ, Lynch JF, Danes BS. Familial atypical multiple mole-melanoma (FAMMM) syndrome: segregation analysis. J Med Genet 1983;20:342-4.
30. Lynch HT, Fusaro RM, Pester J, Oosterhuis JA, Went LN, Rumke P, et al. Tumour spectrum in the FAMMM syndrome. Br J Cancer 1981;44:553-60.
31. Fusaro RM, Lynch HT. The familial atypical multiple mole melanoma syndrome and its associated risk for pancreatic cancer. Int J Pancreatol 1994;16:216-21.
32. Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990;61:932-6.
33. Canon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-51.
34. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlation with phenotype. Hum Mutat 1995;5:66-72.
35. Latif F, Tory K, Gnarra J, Yao M, Duh F, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
36. Glavac D, Neumann HPH, Wittke C, Jaenig H, Masek O, Streicher T, et al. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet 1996;98:271-80.
37. Mecklin J, Jarvinen HJ. Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 1986;29:160-4.
38. Jass JR, Smyrk TC, Stewart SM, Lane MR, Lanspa SJ, Lynch HT. Pathology of hereditary nonopolyposis colorectal cancer. Anticancer Res 1994;14:1631-4.
39. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer, an updated review. Gastroenterology 1993;104:1535-49.
40. Jessurun MR, Manivel JC. Cecal, poorly differentiated adenocarcinomas, medullary-type. Mod Pathol 1992;5:43A.
41. Smyrk TC, Lynch HT, Watson PA, Appelman HD. Histologic features of hereditary nonpolyposis colorectal carcinoma. In: Utsunomiya J, Lynch HT, editors. Hereditary colorectal cancer. Tokyo: Springer-Verlag, 1990.
42. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 1990;3:332-5.
43. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-56.
44. Losi L, Fante R, di Gregorio C, Aisoni ML, Lanza G, Maestri I, et al. Biologic characterization of hereditary nonpolyposis colorectal cancer: nuclear ploidy, AgNOR count, microvessel distribution, oncogene expression, and grade-related parameters. Am J Clin Pathol 1995;103:265-70.
45. Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Onda A, Okumura Y, et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 1996;111:307-17.
46. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
47. Nuffield Council on Bioethics. Genetic screening: ethical issues. London: Nuffield Foundation, 1993.
48. Andrews LB, Fullerton JE, Holtzman NA, Motulsky AG. Assessing genetic risks: implications for health and social policy. Washington, DC: National Academy Press, 1994.
49. Heredity: science and society on the possibilities and limits of genetic testing and gene therpay. Report issued by a committee of the Health Council of the Netherlands. Hum Gen Ther 1994;5:37-40.
50. American Society of Human Genetics. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1995;55:1-4.
51. Working Party of the Clinical Genetics Society. The genetic testing of children. J Med Genet 1994;31:785-97.
52. American Society for Human Genetics, American College of Medical Genetics. Points to consider: ethical, legal and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995;57:1233-41.
53. Harper PS. Genetic testing, common diseases, and health service provision. Lancet 1995;346:1645-6.
54. Ministry of Health and Social Affairs. Biotechnology related to human beings Oslo: Ministry of Health and Social Affairs, 1993.
55. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-6.
56. Castleman B. Case 25, case records of the Massachusetts General Hospital. N Engl J Med 1972;286:1353-9.
57. Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952;21:54-63.
58. Davidson P, Costanza D, Swieconek JA, Harris JB. Hereditary pancreatitis: a kindred without gross aminoaciduria. Ann Intern Med 1968;68:88-96.
59. Madrazo-de la Garza J, Hill ID, Lebenthal E. Hereditary pancreatitis. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber H, Scheele GA, editors. The pancreas: biology, pathobiology, and disease. New York: Raven Press, 1993:1095-101.
60. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990;322:723-7.
61. Lynch HT, Follett K, Shonka M, Marrero K, Fain P, Lynch J. Familial colon cancer in two high risk Nebraska counties. [abstract]. Proc AACR, San Diego, 1980.
62. Fitzgibbons RJ Jr., Lynch HT, Stanislav GV, Watson P, Lanspa SJ, Marcus JN, et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch Syndromes I and II). Ann Surg 1987;206:289-95.
63. Lynch HT, Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991;6:127-31.
64. Binkovitz LA, Johnson DC, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol 1990;155:501-5.
65. Hough DM, Stephens DH, Johnson CD, Binkovitz LA. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol 1994;162:1091-4.
66. Burke W, Bennett RL, Schmidt R, Dellinger E, Evans JP. Autosomal dominant transmission of pancreatic cancer with diabetes and exocrine insufficiency in a large kindred [abstract 191]. Am J Hum Genet 1992;51:50.
67. Evans JP, Burke W, Chen R, Bennett RL, Schmidt RA, Dellinger EP, et al. Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet 1995;32:330-5.